Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

ATTO

$15.582.57%0.39

Atento S.A. Ordinary Shares (ATTO)

Date: O: H: L: C: Vol:

Atento S.A. Ordinary Shares Aktie (ATTO) Neueste Nachrichten

ATTO Price Today: Attovia Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia

No ownership changes: Attovia Therapeutics (ATTO) CEO Tao Fu reports 87,843 direct shares. - Stock Titan

Attovia Therapeutics (ATTO) amends CFO option-grant report with no ownership changes. - Stock Titan

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire

Goldman units trade Attovia Therapeutics (ATTO) shares, add swaps - Stock Titan

Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock - Stock Titan

Atento S.A. (OTC: ATTOF) Stock Price, News & Analysis - kalkine.ca

Goldman Sachs entities (NYSE: ATTO) report Attovia stock conversions and market-making trades - Stock Titan

Frazier Life Sciences XI Discloses Investment at Attovia Therapeutics with 13.5% Stake - tradingview.com

Frazier Life Sciences funds (ATTO) detail Attovia stakes and IPO purchases - Stock Titan

Attovia Therapeutics (ATTO) insider reports initial stock and option holdings - Stock Titan

Attovia Therapeutics (ATTO) major holder converts 18.2M preferred into common - Stock Titan

Attovia Therapeutics (ATTO) director discloses 72,792-share option grant and vesting terms - Stock Titan

ATTO SEC Filings - Attovia Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Attovia Therapeutics (ATTO) CMO Hubert Chen discloses stock and option positions - Stock Titan

Attovia Therapeutics, Inc. Common Stock (ATTO) Stock Price: Oct 20 Close $14.04 - Gotrade

Attovia Therapeutics (Nasdaq:ATTO) - Stock Analysis - Simply Wall Street

Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - finance.yahoo.com

Attovia Therapeutics Prices Upsized $289 Million Initial Public Offering - Quiver Quantitative

Attovia Therapeutics prices IPO at $17 per share on Nasdaq By Investing.com - Investing.com Nigeria

Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com India

Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO - Fierce Biotech

Attovia Therapeutics prices upsized IPO at $17 per share - Investing.com

Attovia's 17M-share IPO is expected to begin Nasdaq Global Market trading Aug. 5 - Stock Titan

Attovia Therapeutics prices IPO at $17 per share on Nasdaq - Investing.com

Redmile Group (ATTO) reports Series B preferred stake convertible into 782,854 shares - Stock Titan

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance Singapore

Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive

Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs - Seeking Alpha

Attovia Therapeutics Begins IPO Effort On Promising Early Trials (ATTO) - Seeking Alpha

Attovia Therapeutics files for IPO on Nasdaq - Investing.com

Attovia Therapeutics files for IPO on Nasdaq By Investing.com - Investing.com Nigeria

Atento SA stock (LU0992182062): Why Google Discover changes matter more now - AD HOC NEWS

Atento SA stock (LU0992182062): Why mobile-first delivery now matters more for customer experience i - AD HOC NEWS

Atento SA Stock (ISIN: LU0992182062) Faces Uncertainty Amid Sparse Market Activity - AD HOC NEWS

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK

Attovia Therapeutics, Inc. (ATTO) Stock Price, News, Quote & History - Yahoo Finance

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia

Ähnlich wie ATTO

AVBP$14.125.04%